IT Finance & Controlling Director

AXQ Capital LP acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, Holdings Channel reports. The firm acquired 27,106 shares of the biopharmaceutical company’s stock, valued at approximately $3,425,000. A number of other hedge funds have also made changes to their positions in the business. Strategic Investment Solutions […]

Eikon Therapeutics appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin ("CP") Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicine, foundational research, and drug discovery. He joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology. "CP is an exceptional physician-scientist whose pioneering basic research in developmental genetics and cardiomyopathies while a student, post-doctoral fellow, and faculty member at Stanford University led to leadership roles in the biopharmaceutical industry, where he demonstrated an ability to translate deep insights about human disease biology into transformative therapies," said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer of Eikon Therapeutics. "His scientific judgment, translational expertise, and experience building high-performing research organizations will be invaluable as we apply our differentiated discovery capabilities to create important new medicines." Prior to joining Bristol Myers Squibb, Dr. Chang served as Head of Cardiovascular Research at Gilead Sciences and then as Vice President of Disease Biology at MyoKardia, where he built a disease biology program focused on understanding and targeting the genetic causes of cardiomyopathies and the characterization of mavacamten, which was later approved for the treatment of hypertrophic cardiomyopathy. "It's an honor to join Eikon and work alongside leaders who have helped develop some of the most important medicines of our time," said Dr. Chang. "This is an exciting moment for the company as its late-stage portfolio advances and technology and AI opens new possibilities across drug discovery and development. With its ability to generate novel biological data at exceptional scale, Eikon is well positioned to capitalize on these advances and bring breakthrough therapeutics to patients with serious illnesses." In addition to his industry experience, Dr. Chang built an accomplished academic career centered on developmental genetics, especially as related to cardiomyopathies. He established his own laboratory at Stanford to study genetic, epigenetic, and RNA-based mechanisms underlying abnormal cardiovascular development and heart failure. He later moved his laboratory to Indiana University School of Medicine where he held the Charles Fisch Endowed Chair of Cardiology and also directed Molecular and Translational Medicine at the Krannert Institute of Cardiology. Dr. Chang completed his medical degree at National Taiwan University before moving to the United States, where he earned his Ph.D. in cancer biology at Stanford University, focusing on molecular interactions between protooncogenes and oncogenic mechanisms. He went on to complete medical residency training at Massachusetts General Hospital, a cardiology fellowship at Stanford University, and a physician-scientist research fellowship at the Howard Hughes Medical Institute, a training arc that grounded him both in clinical practice and in fundamental research. About Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon's vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com. Forward-Looking/Safe Harbor Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon's product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond; and other statements regarding Eikon's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. These forward-looking statements are based upon management's current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption "Risk Factors" and elsewhere in Eikon's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission ("SEC") on August 13, 2026, and in other public filings with the SEC in the future. As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law. Investors Alfred "Freddie" Bowie, Ph.D., CFO [email protected]

A new once-daily pill to treat HIV just got the FDA's green light. Desiree Guerrero Mon, August 31, 2026 at 1:31 PM PDT On Thursday, the Food and Drug Administration announced it has approved a new once-daily, single-pill HIV treatment, according to a report by CNBC. The new pill, called Bixlenvo and created by Gilead Sciences, is an especially exciting development for people living with HIV because it provides them with another treatment option that contains a minimal amount of drugs. It combines bictegravir, the active ingredient in Gilead's super successful HIV treatment Biktarvy, with lenacapavir, a capsid inhibitor that has become a key component in Gilead's HIV treatment and prevention methods. The new treatment is aimed at individuals whose HIV is already under control but who are still dealing with complicated treatment regimens. The FDA's approval makes it the first single-pill regimen available for HIV+ adults whose virus is suppressed but who, for various reasons, are unable to use any of the single-pill treatments currently on the market, as noted in Gilead's announcement. This represents about five percent of people living with HIV in the U.S. This group is mostly comprised of older individuals with long treatment histories, says Dr. Jared Baeten, Gilead's clinical development and virology therapeutic area head. He notes that many of these people "had to take handfuls of pills around 25 years ago," in addition to the fact that HIV can accelerate other complications of aging, like heart disease, diabetes, and high cholesterol. "It fulfills an unmet need, particularly for individuals who are on complex regimens who just would not otherwise consolidate down to something really meaningful for them and prescribers," Baeten told CNBC. "But it's also meaningful for individuals who are seeking options for something new," he added, commenting on its viability as a treatment option for others outside of this demographic. "We want to build options that give people the opportunity to choose something that's going to work for them and work for them for the long haul." Before discounts or rebates, the list price of Bixlenvo is $4,595 for a one-month supply, which is similar to other daily single-pill treatments. Those without health coverage may be eligible to receive it for free through Gilead's patient assistance program, and people with insurance may be eligible for copay support. Timothy Cameron, a retired Seattle resident who participated in the first Phase 3 trial, also spoke to CNBC about the exciting development. Cameron, 64, has been living with HIV for more than 40 years. He says when he was first diagnosed in the 1980s, very few treatment options existed, and it was difficult for doctors to measure exactly how active the virus. He was prescribed various HIV treatments over the years, including experimental drugs and multi-pill regimens that often came with serious side effects. However, they all would eventually cease to control his "hard-to-treat" HIV. "It was just like throwing darts at a dartboard," Cameron said. "Because I had done so many drug trials and monotherapy, my virus had become super resistant." Fortunately, he survived those difficult years and finally found a regimen that controlled his HIV, but it required him to take a pill twice a day along with another drug. Then a few years ago, his doctor encouraged him to join the trial and switch to Bixlenvo. Cameron says the transition was seamless and the new regimen has maintained control of his HIV without any notable side effects. Switching to the once-daily pill "smaller than my pinky nail" was a welcome relief after decades of treatment struggles "It's one less thing I'm putting in my body, and it preserves options if I need them," Cameron said.